Proactive Investors - Run By Investors For Investors

Redx Pharma's CSO Richard Armer outlines development ambitions and clinical targets

Redx Pharma Plc's (LON:REDX) chief scientific officer Richard Armer sat down with Proactive London's Andrew Scott to discuss the opportunities ahead for their cancer and fibrosis portfolios.

Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

 
Meet Cardinal Resources Ltd and Legend Mining Ltd at our event, Melbourne , 16 July 2019. Register here »
View full REDX profile View Profile

Redx Pharma Plc Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use